# KRAZATI

NDC: 80739-812
Generic name: adagrasib
Labeler / Manufacturer: Mirati Therapeutics, Inc
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, COATED
Routes: ORAL
Marketing started: 20221212

FDA application: NDA216340

## Active ingredients

- ADAGRASIB: 200 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"80739-812"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=80739-812
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01